Skip to content

Exploratory Study on Phage Therapy for Pseudomonas aeruginosa Infections in Cystic Fibrosis and Primary Ciliary Dyskinesia

Exploratory Study on Phage Therapy for Pseudomonas aeruginosa Infections in Cystic Fibrosis and Primary Ciliary Dyskinesia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500104474
Enrollment
Unknown
Registered
2025-06-18
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pseudomonas aeruginosa

Interventions

Sponsors

Shanghai Children's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age >= 28 days; 2. Confirmed diagnosis of cystic fibrosis (CF) based on the Chinese Expert Consensus on the Diagnosis and Treatment of Cystic Fibrosis (2023) or primary ciliary dyskinesia (PCD) based on the Chinese Expert Consensus on the Diagnosis and Treatment of Primary Ciliary Dyskinesia (2020); 3. Detection of Pseudomonas aeruginosa in lower respiratory tract secretions or bronchoalveolar lavage fluid (BALF), as defined by the Chinese Expert Consensus on the Diagnosis and Treatment of Pseudomonas aeruginosa Lower Respiratory Tract Infections (2022); 4. No contraindications for nebulized inhalation or bronchoscopy; 5. Availability of at least one lytic bacteriophage active against the isolated Pseudomonas aeruginosa strain; 6. Written informed consent obtained from the participant (or legally authorized guardian for minors/incapacitated individuals) after full explanation of the study.

Exclusion criteria

Exclusion criteria: 1. Severely abnormal vital signs at screening; 2. Any primary or secondary immunodeficiency state (including drug-induced), if the degree of immunosuppression exceeds the typical levels associated with cystic fibrosis (CF)/primary ciliary dyskinesia (PCD) or their standard treatments; 3. Severe neutropenia, defined as an absolute neutrophil count (ANC) < 500/µL; 4. Prior bacteriophage therapy within 3 months before screening; 5. Participation in another interventional clinical trial within 3 months before screening; 6. Investigator-determined unsuitability for study participation.

Design outcomes

Secondary

MeasureTime frame
Clinical symptom relief rate;Acute systemic antibiotic usage rate;Phage activity level;

Primary

MeasureTime frame
Change in the Pseudomonas aeruginosa load;Change in Pulmonary Function Indices (ppFEV1, FEV1, etc.) from Baseline;

Countries

China

Contacts

Public ContactLiling Qian

Shanghai Children's Hospital

llqian@126.com+86 180 1759 1188

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026